LRRK2 G2019S as a Cause of Parkinson's Disease in North African Arabs

doi:10.1056/NEJMc055540

Volume 354:422-423		January 26, 2006		Number 4

LRRK2 G2019S as a Cause of Parkinson's Disease in North African Arabs

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

PDF

PDA Full Text

Supplementary Material

Purchase this article

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

PubMed Citation

To the Editor: Parkinson's disease is characterized by restingtremor, rigidity, and bradykinesia caused by the loss of dopaminergicneurons in the substantia nigra, a good response to levodopa,and the presence of Lewy bodies. The recently identified G2019Smutation in exon 41 of the leucine-rich repeat kinase 2 gene(LRRK2) accounts for 2 to 6 percent of familial and 1 to 2 percentof sporadic cases.¹ The mutation is less common in Asian populations¹but prevalent in patients from North Africa who have Parkinson'sdisease, as we describe here.

We obtained blood samples from 104 unrelated index . . . [Full Text of this Article]

This article has been cited by other articles:

Sieh, W., Choi, Y., Chapman, N. H., Craig, U.-K., Steinbart, E. J., Rothstein, J. H., Oyanagi, K., Garruto, R. M., Bird, T. D., Galasko, D. R., Schellenberg, G. D., Wijsman, E. M. (2009). Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Hum Mol Genet 18: 3725-3738 [Abstract] [Full Text]
Ng, C.-H., Mok, S. Z. S., Koh, C., Ouyang, X., Fivaz, M. L., Tan, E.-K., Dawson, V. L., Dawson, T. M., Yu, F., Lim, K.-L. (2009). Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila. J. Neurosci. 29: 11257-11262 [Abstract] [Full Text]
Saha, S., Guillily, M. D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., Hsu, C. H., Segal, L., Raghavan, K., Matsumoto, K., Hisamoto, N., Kuwahara, T., Iwatsubo, T., Moore, L., Goldstein, L., Cookson, M., Wolozin, B. (2009). LRRK2 Modulates Vulnerability to Mitochondrial Dysfunction in Caenorhabditis elegans. J. Neurosci. 29: 9210-9218 [Abstract] [Full Text]
Lesage, S, Condroyer, C, Lannuzel, A, Lohmann, E, Troiano, A, Tison, F, Damier, P, Thobois, S, Ouvrard-Hernandez, A-M, Rivaud-Pechoux, S, Brefel-Courbon, C, Destee, A, Tranchant, C, Romana, M, Leclere, L, Durr, A, Brice, A, for the French Parkinson's Disease Genetics Study, (2009). Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease. J. Med. Genet. 46: 458-464 [Abstract] [Full Text]
Olanow, C. W., Stern, M. B., Sethi, K. (2009). The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72: S1-S136 [Abstract] [Full Text]
Lesage, S., Brice, A. (2009). Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18: R48-R59 [Abstract] [Full Text]
Marek, K., Jennings, D. (2009). Can we image premotor Parkinson disease?. Neurology 72: S21-S26 [Abstract] [Full Text]
Gasser, T. (2009). Genomic and proteomic biomarkers for Parkinson disease. Neurology 72: S27-S31 [Abstract] [Full Text]
Healy, D G, Wood, N W, Schapira, A H V (2008). Test for LRRK2 mutations in patients with Parkinson's disease. PN 8: 381-385 [Abstract] [Full Text]
Lesage, S., Belarbi, S., Troiano, A., Condroyer, C., Hecham, N., Pollak, P., Lohman, E., Benhassine, T., Ysmail-Dahlouk, F., Durr, A., Tazir, M., Brice, A., For the French Parkinson's Disease Genetics Study, (2008). Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?. Neurology 71: 1550-1552 [Full Text]
Greggio, E., Zambrano, I., Kaganovich, A., Beilina, A., Taymans, J.-M., Daniels, V., Lewis, P., Jain, S., Ding, J., Syed, A., Thomas, K. J., Baekelandt, V., Cookson, M. R. (2008). The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation. J. Biol. Chem. 283: 16906-16914 [Abstract] [Full Text]
Haugarvoll, K., Rademakers, R., Kachergus, J. M., Nuytemans, K., Ross, O. A., Gibson, J. M., Tan, E-K, Gaig, C., Tolosa, E., Goldwurm, S., Guidi, M., Riboldazzi, G., Brown, L., Walter, U., Benecke, R., Berg, D., Gasser, T., Theuns, J., Pals, P., Cras, P., De Deyn, P. P., Engelborghs, S., Pickut, B., Uitti, R. J., Foroud, T., Nichols, W. C., Hagenah, J., Klein, C., Samii, A., Zabetian, C. P., Bonifati, V., Van Broeckhoven, C., Farrer, M. J., Wszolek, Z. K. (2008). Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70: 1456-1460 [Abstract] [Full Text]
Chen-Plotkin, A. S., Yuan, W., Anderson, C., Wood, E. M., Hurtig, H. I., Clark, C. M., Miller, B. L., Lee, V. M.-Y., Trojanowski, J. Q., Grossman, M., Deerlin, V. M. V. (2008). Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 70: 521-527 [Abstract] [Full Text]
Lesage, S, Lohmann, E, Tison, F, Durif, F, Durr, A, Brice, A, for the French Parkinson's Disease Genetics Study, (2008). Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J. Med. Genet. 45: 43-46 [Abstract] [Full Text]
Klein, C., Schlossmacher, M. G. (2007). Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder. Neurology 69: 2093-2104 [Abstract] [Full Text]
Charles, P., Camuzat, A., Benammar, N., Sellal, F., Destee, A., Bonnet, A-M, Lesage, S., Le Ber, I., Stevanin, G., Durr, A., Brice, A., French Parkinson's Disease Genetic Study Group, (2007). Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism?. Neurology 69: 1970-1975 [Abstract] [Full Text]
Orr-Urtreger, A., Shifrin, C., Rozovski, U., Rosner, S., Bercovich, D., Gurevich, T., Yagev-More, H., Bar-Shira, A., Giladi, N. (2007). The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: Is there a gender effect?. Neurology 69: 1595-1602 [Abstract] [Full Text]
Luzon-Toro, B., de la Torre, E. R., Delgado, A., Perez-Tur, J., Hilfiker, S. (2007). Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet 16: 2031-2039 [Abstract] [Full Text]
Lesage, S., Janin, S., Lohmann, E., Leutenegger, A.-L., Leclere, L., Viallet, F., Pollak, P., Durif, F., Thobois, S., Layet, V., Vidailhet, M., Agid, Y., Durr, A., Brice, A., for the French Parkinson's Disease Genetics Study, (2007). LRRK2 Exon 41 Mutations in Sporadic Parkinson Disease in Europeans. Arch Neurol 64: 425-430 [Abstract] [Full Text]
West, A. B., Moore, D. J., Choi, C., Andrabi, S. A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.-L., Dawson, V. L., Dawson, T. M. (2007). Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16: 223-232 [Abstract] [Full Text]
Clark, L. N., Wang, Y., Karlins, E., Saito, L., Mejia-Santana, H., Harris, J., Louis, E. D., Cote, L. J., Andrews, H., Fahn, S., Waters, C., Ford, B., Frucht, S., Ottman, R., Marder, K. (2006). Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 67: 1786-1791 [Abstract] [Full Text]
Tan, E.-K., Jankovic, J. (2006). Genetic testing in Parkinson disease: promises and pitfalls.. Arch Neurol 63: 1232-1237 [Full Text]
Ishihara, L., Warren, L., Gibson, R., Amouri, R., Lesage, S., Durr, A., Tazir, M., Wszolek, Z. K., Uitti, R. J., Nichols, W. C., Griffith, A., Hattori, N., Leppert, D., Watts, R., Zabetian, C. P., Foroud, T. M., Farrer, M. J., Brice, A., Middleton, L., Hentati, F. (2006). Clinical Features of Parkinson Disease Patients With Homozygous Leucine-Rich Repeat Kinase 2 G2019S Mutations.. Arch Neurol 63: 1250-1254 [Abstract] [Full Text]
(2006). Papers of Note. Sci Aging Knowl Environ 2006: nw5-nw5 [Full Text]
Ozelius, L. J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., Hunt, A. L., Klein, C., Henick, B., Hailpern, S. M., Lipton, R. B., Soto-Valencia, J., Risch, N., Bressman, S. B. (2006). LRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews. NEJM 354: 424-425 [Full Text]

Comments and questions? Please contact us.